FDA Proposes Chinese Label Translation Requirement for US Sports Supplements

FDA has proposed new labeling requirements for dietary supplements marketed in the U.S., specifically targeting products with Chinese-language labels — including sports nutrition items such as protein powders, BCAAs, and energy gels. Effective April 16, 2026, the draft guidance introduces a mandatory FDA备案 translation process, signaling potential operational and cost implications for manufacturers, exporters, and brand owners engaged in the U.S.-China supplement supply chain.

Event Overview

On April 16, 2026, the U.S. Food and Drug Administration (FDA) released the Draft Guidance on Dietary Supplement Labeling. This document proposes that all dietary supplements sold in the U.S. bearing Chinese-language labeling must submit an English translation to the FDA for备案 (registration/acknowledgement), and that the label must include the statement: ‘Translation verified by FDA-registered translator’. The draft is currently open for public comment and has not yet been finalized.

Industries Affected

Contract Manufacturers (OEM/ODM Facilities in China)

Chinese contract manufacturers producing private-label sports supplements for U.S.-based brands will be directly impacted. Since many export products carry bilingual (English + Chinese) labels — often for domestic marketing or logistics clarity — this requirement applies even when Chinese text appears only on inner packaging, cartons, or documentation accompanying bulk shipments. Compliance will necessitate formal translation submission and verification for each SKU, increasing administrative burden and traceability requirements.

U.S.-Based Supplement Brands Using Chinese Contract Manufacturing

Brands relying on Chinese OEM partners face new upstream compliance responsibilities. Under the draft, the ‘responsible party’ listed on the supplement label (typically the U.S. distributor or importer) remains legally accountable for label accuracy — including translated content. This shifts verification obligations upstream, requiring brands to coordinate closely with manufacturers and translators to ensure alignment with FDA expectations before product release.

Translation & Regulatory Support Providers

The proposal introduces a de facto qualification layer for translation service providers. While the term ‘FDA-registered translator’ is not defined in current regulations, the draft implies that translators may need to self-register or be vetted through an FDA-recognized system. This could reshape demand for specialized regulatory linguists and prompt third-party verification platforms to develop compliant workflows — though no official registry or accreditation mechanism has been announced.

What Stakeholders Should Monitor and Do Now

Track the finalization timeline and scope clarifications

The draft remains non-binding. Stakeholders should monitor FDA’s docket (Docket No. FDA-2026-D-XXXXX, if assigned) for updates, public comment summaries, and any revised language — especially regarding whether the requirement extends beyond consumer-facing labels (e.g., to shipping labels, certificates of analysis, or internal documentation).

Review current label versions across SKUs and packaging tiers

Companies should audit all products destined for the U.S. market to identify where Chinese text appears — including outer boxes, inner pouches, instruction inserts, and digital assets linked via QR codes. Even incidental Chinese characters (e.g., manufacturer names, lot codes, or certifications) may fall under scrutiny depending on how FDA interprets ‘labeling’ under 21 CFR §101.95.

Distinguish between policy signal and enforceable rule

This is a draft guidance, not a regulation. It reflects FDA’s current thinking but does not carry the force of law until codified. Companies should avoid premature investment in unverified ‘FDA-registered translator’ services and instead prioritize documentation of existing translation processes, including translator credentials and quality assurance steps.

Prepare internal coordination protocols for translation submission

For companies managing multiple SKUs, begin mapping translation ownership (brand vs. manufacturer vs. third-party), version control for label iterations, and record retention practices. Anticipate that FDA may require submission of translation files alongside facility registrations or prior notice submissions — making early process alignment critical.

Editorial Perspective / Industry Observation

From industry perspective, this draft guidance is best understood as a regulatory signal — not an immediate compliance mandate. It reflects growing FDA attention to multilingual labeling integrity, particularly in categories with high import volume and documented labeling violations (e.g., undeclared ingredients, structure/function claims). Analysis来看, the $320 per-SKU cost estimate cited in the summary likely includes translation, verification, documentation, and internal review time — but actual costs will vary significantly based on label complexity and existing vendor relationships. Observation来看, FDA has not yet defined what constitutes an ‘FDA-registered translator’, nor indicated whether it plans to establish a formal registry. Current more appropriate interpretation is that FDA seeks greater accountability for translation accuracy — not necessarily centralized credentialing — at least in the near term.

Conclusion

This draft guidance marks a procedural shift rather than a substantive change in labeling science or safety standards. Its significance lies in reinforcing FDA’s expectation that all label elements — regardless of language — must be subject to verifiable quality control. For now, it is more accurately read as a notice of intent and a call for stakeholder input than as an impending enforcement threshold. A measured, documentation-first response — aligned with existing Good Manufacturing Practice (GMP) and labeling recordkeeping requirements — remains the most pragmatic approach.

Information Source

Main source: U.S. FDA, Draft Guidance on Dietary Supplement Labeling, issued April 16, 2026. Note: This is a draft document; final requirements, effective dates, and implementation details remain pending FDA review and public comment. No official translator registry or fee structure has been published as of the draft release date.